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Abstract
Background: The RANK ligand inhibitor denosumab is being investigated for treatment of giant cell tumor of
bone, but the available data in the literature remains sparse and controversial. This study analyzes the results of
combining denosumab with surgical treatment and highlights possible changes for the oncologic surgeon in daily
practice.
Methods: A total of 91 patients were treated surgically for giant cell tumor of bone between 2010 and 2014 in an
institution, whereas 25 patients of the total additionally received denosumab and were part of this study. The
average age of the patients was 35 years. Eleven patients received denosumab pre- and postoperatively, whereas
with 14 patients, the denosumab treatment was applied either before (7 patients) or after (7 patients) the surgery.
The average preoperative therapy duration was 3.9 months and the postoperative therapy 6 months by default.
Results: Sixteen patients presented a large tumor extension necessitating a resection of the involved bone or joint.
In 10 of these patients, the indication for a resection procedure was abandoned due to the preoperative denosumab
treatment and a curettage was performed. In the remaining six cases, the surgical indication was not changed despite
the denosumab treatment, and two of them needed a joint replacement after the tumor resection. Also with patients
treated with curettage, denosumab seems to facilitate the procedure as a new peripheral bone rim around the tumor
was built, though a histologic analysis reveals viable tumor cells persisting in the denosumab-induced bone formation.
After an average follow-up of 23 months, one histologically proven local recurrence occurred, necessitating a second
curettage. A second patient showed a lesion in the postoperative imaging highly suspicious for local relapse which
remained stable under further denosumab treatment. No adverse effect of the denosumab medication was observed
in this study.
Conclusions: Denosumab can be a help to the oncologic surgeon by reconstituting a peripheral rim and switching
the stage from aggressive to active or latent disease. But as tumor cells remain in the new-formed bone, the surgical
technique of curettage has to be changed from gentle to more aggressive to avoid higher local recurrence rates.
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Background
Giant cell tumor of bone (GCTB) is a primary benign
lesion with local aggressive behavior, affecting usually
young adults. GCTB accounts for approximately 5 % of
all bone tumors and 20 % of all benign tumors with a
slight preference for females [1, 2].
The disease commonly presents as an epiphyseal, lytic
lesion most often localized in the distal femur, proximal
tibia, and distal radius [1]. It is characterized by progres-
sive growth and bone lysis with relatively well-defined
margins. The cortex of the involved bone is usually
thinned, often expanded, and sometimes breached with
or without soft tissue expansion [3].
The clinical course is unpredictable if untreated, be-
cause of possible mechanical load failure and joint
function compromise. By 1–4 % of all patients affected
by GCTB pulmonary metastases are detected even
when the histologic appearance remains benign [4].
The tumor tissue consists of two different cell popula-
tions: First, the multinucleated giant cells, which are dif-
fusely distributed throughout the tumor mass and which
are responsible for the disease typical massive bone absorp-
tion [5]. Second, mononucleated fibrous cells are found
with an oval or fusiform shape, which not only present a
proliferative activity and neoplastic cytogenetic anomalies
but also promote the formation and activation of the giant
cells from precursor cells [5].
Surgical removal of the lesion remains to date the only
curative treatment for GCTB [6]. Most of the times, a
local curettage is performed, followed by stuffing the
bone defect with bone cement or bone graft and prophy-
lactic internal fixation. But in some advanced GCTB, the
tumor lesion is too extended for a simple curettage, ne-
cessitating an en bloc excision of the involved bone and
joint [7]. Even if different surgical techniques are available
for the following reconstruction, significant functional
impairment and surgical morbidity cannot be completely
avoided [8].
Denosumab, a monoclonal antibody inhibiting the
receptor activator of nuclear factor-kappa β ligand
(RANKL), first introduced for the treatment of severe
osteoporosis [9], has been recently approved for the
application in patients with GCTB [10].
RANKL is an essential cytokine for the formation,
function, and survival of osteoclasts [11]. Denosumab in-
hibits the interaction between RANKL, continuously
expressed by the tumor stromal cells, and its receptor
(RANK) on the osteoclasts. In this manner, the progres-
sion of bone resorption and osteolytic tumor expansion is
reversibly blocked [12]. These molecular changes corre-
lated with new bone formation and increased radiologic
density on CT scans [13].
In the current practice, denosumab is provided to
patients with GCTB that is classified as “unresectable”
or to avoid large surgical resection with severe morbidity.
As denosumab is a relatively new treatment for GCTB,
the literature is still sparse regarding indication, as well as
timing and duration of the drug application.
This study focuses on the risks and benefits of denosu-
mab for the treating oncologic surgeon. In contrast to
the previous studies [13, 14], all included patients under-
went a surgical procedure already indicated at diagnosis,
giving denosumab the role of an adjuvant treatment
comparable to radiation therapy in soft tissue sarcomas.
Methods
Patients
A total of 91 patients underwent surgery for GCTB be-
tween 2010 and 2014 in one institution. Of them, 25 pa-
tients (26.6 %) received denosumab either preoperative,
postoperative, or at both stages and were included in the
study. The prospective gathered patient’s data was
retrospectively reviewed. Both indication and sequence
of surgery and denosumab treatment were individually
discussed and defined in a multidisciplinary board. Pre-
operative denosumab treatment was applied in the fol-
lowing situations:
 Large tumor extension necessitating a bone
resection
 Local advanced disease with a high risk for local
recurrence after curettage
 Anatomic locations with impending pathologic
fractures, for example, pelvis, femoral head, and foot
If the surgical removal of the tumor was difficult to
achieve in these situations and some residual disease
was suspected, the denosumab treatment was continued
postoperatively. In some cases, the preoperative imaging
did not correspond to the intraoperative findings. Accord-
ing to the radiologic findings, the tumor was assessed as
easily removable and no neo-adjuvant treatment was
performed. But the intraoperative situs revealed a much
more advanced disease than expected. These patients
received postoperative denosumab only for minimizing
the risk of local recurrence and stabilization of the clin-
ical course.
Denosumab treatment was not considered if the
GCTB was easily accessible by simple curettage. Distinct
contraindications for denosumab application included
skeletal immaturity, anamnestic active dental or jaw
problems, and pregnancy.
The average age of the patients was 35.4 years (range
15–72 years). The tumor was found most frequently in
the distal femur (seven cases; 29.2 %), followed by the
distal and proximal tibia with three cases each (12.5 %).
A more detailed overview of the patients is given in
Table 1.
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Treatment
The diagnosis of GCTB was always confirmed by a
CT-guided core needle biopsy. The preoperative tumor
extension was assessed by conventional X-ray, CT, and
MRI scans. In all the included cases, the tumor was classi-
fied as stage 3 according to the Enneking classification for
benign bone tumors [15].
Patients received open-label subcutaneous denosumab
120 mg every 4 weeks, with additional doses adminis-
tered on days 8 and 15 during the first month of therapy
only. For patients who received also a postoperative
treatment, denosumab therapy continued for six additional
doses after surgery.
Planned surgical procedures were recorded before the
application of denosumab and compared to the actual
performed surgery. Procedure selection and timing were
based on serial review of imaging studies and individual
assessment by the oncologic surgeon.
Postoperatively, patients were examined clinically and
radiologically every 3 months during the first 2 years and
every 6 months after 2 years.
Results
The enrolled patients were observed for a mean follow-
up of 23 months (9–49 months).
Denosumab treatment
The denosumab therapy was applied in 11 patients (44 %)
both pre- and postoperatively, whereas in 7 patients
(2 × 28 %), the treatment was either pre- or postoperative.
The mean preoperative therapy duration was 3.9 months
(range 3–6 months) and the postoperative therapy 6 months
by default.
No adverse effect or any complication due to the
denosumab treatment was observed. Four cases (16 %)
showed local progression of disease under denosumab
therapy and were therefore classified as “non-responder”.
Surgery
In 16 patients (64 %), a resection of the involved bone or
joint was indicated as the tumor extension was too large
for a curettage procedure. After the preoperative deno-
sumab treatment, the decision of the surgical procedure
Table 1 Patient demographics
Patient Gender Age (years) Follow-up (months) Localization Denosumab preoperative Denosumab postoperative
1 F 30 36 Distal humerus Yes Yes
2 M 31 43 Femoral head No Yes
3 F 65 21 Distal tibia Yes Yes
4 M 51 33 Distal radius No Yes
5 M 72 32 Distal femur No Yes
6 M 32 17 Distal femur Yes Yes
7 F 16 33 Patella Yes No
8 F 19 41 Distal tibia Yes No
9 M 62 31 Metacarpal bone Yes No
10 F 21 31 Proximal tibia Yes No
11 F 15 49 Proximal tibia Yes Yes
12 M 62 27 Distal radius Yes Yes
13 M 29 19 Distal femur Yes Yes
14 F 40 17 Sacrum Yes Yes
15 M 27 21 Proximal tibia No Yes
16 F 27 14 Proximal fibula Yes Yes
17 M 27 14 Proximal radius Yes Yes
18 F 44 15 Proximal fibula Yes No
19 F 30 13 Distal femur Yes Yes
20 M 31 13 Distal femur Yes No
21 M 25 9 Distal tibia Yes Yes
22 M 46 14 Distal femur No Yes
23 M 22 10 Calcaneus No Yes
24 F 37 10 Distal femur No Yes
25 F 23 13 Iliac wing Yes No
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was changed in 10 out of these 16 cases and the indication
for a resection was abandoned. During the preoperative
denosumab therapy, repeated MRI and CT scans were
performed. The surgical indication was changed if a rele-
vant shrinkage of the lesion was observed or the rim
showed advanced ossifications. In either way, the stability
of the involved bone was improved, and a curettage was
possible now. All these cases were therefore described as
“surgical downstaging” (Fig. 1).
In six cases (24 %), the indication for resection was
not changed despite denosumab treatment. But in four
patients, the resection was less invasive and easier to
perform according to the surgeon’s appreciation, even if
the extension into the soft tissues was advanced in these
cases. Denosumab has led to an ossification of the soft
tissue mass, facilitating the en bloc resection. Increased
bone density simplifies the intraoperative manipulation
and prevents an unintended burst of the tumor.
In four out of six resections, no further reconstruction
was needed, as the resected bone was not mechanically
relevant for weight-bearing. In the remaining two cases,
one affecting the proximal radius and one the proximal
tibia, an allograft prosthetic composite was done to restore
the joint function (Fig. 2).
A total of 19 patients (76 %) underwent a local, surgi-
cal aggressive curettage: After the removal of the tumor
mass with spoons, the residual rim was removed with a
high-speed burr and the cavity was instilled with liquid
phenol. In 18 out of 19 patients, an additional cryother-
apy was applied: First, a sterile thermoconducting gel,
routinely used in urology and gynecology, was inserted
in the cavity. Afterwards, several probes were placed in-
side the liquid gel. The temperature at the tip of the
prone was successively decreased by the help of Argon
to −100 °C, creating a controlled “iceball” around the
probe (Fig. 3). After 5 min, the temperature was raised
again to 35 °C. This cycle was repeated two times, chan-
ging the position of the probes in each cycle.
For nine patients (36 %), a curettage was indicated
already before beginning the denosumab therapy. With
seven patients (28 %), the surgeon rated the performed
curettage as less extensive than planned on the primary
radiographs.
More details about the surgical treatment of every case
are given in Table 2.
Local recurrence
One histologically proven local recurrence was observed
(4 %). The patient (case nr. 7) underwent a curettage of
the patella, and a local relapse occurred 7 months post-
operatively. The relapse was found in the periphery of
the patella towards the joint surface, which raises the
question if the curettage was done properly. After a second
curettage, the patient was disease free at the last follow-up.
Patient nr. 1 showed radiologic changes 6 months after
curettage at the distal humerus, highly suspicious for
local recurrence. The patient preferred the continu-
ation of the denosumab treatment instead of a revision
surgery. At the last follow-up, no clinical or radiological
progression was seen.
Histologic changes
In all the cases who received preoperative denosumab
treatment, the microscopic morphologic appearance of the
intraoperative specimen was completely different compared
to the preoperative biopsy sample (Fig. 4). The osteoclast-
like giant cells disappeared almost completely. The residual
tumor consisted mainly of spindle cells without any atypia,
often organized in a storiform pattern. Besides the cellular
component, regions of collagen matrix formation were
seen. The collagen presented a diffuse or a honeycomb/tra-
becular archetype fusing with osteoid formation.
Fig. 1 Surgical decision-making process. Schematic illustration showing the surgical decision-making process. The first line is indicating the
planned surgical procedure before denosumab treatment (“intention to treat”). The second line shows the actual performed surgery after
denosumab treatment (“performed surgery”)
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These two different zones were not distributed randomly
but arranged in a centrifugal pattern, with cellular areas in
the center and matrix forming areas at the periphery of the
tumor.
In 11 of the patients (45.8 %), a detailed genotype ana-
lysis and immunohistochemical staining was performed
[16]. From a surgical point of view, the most interesting
findings were a significant reduction in microvascular
density of the post-denosumab specimen and a significant
overall decrease of the cellular proliferation index [16].
Discussion
GCTB is a rare, epidemiologic, and clinically well-
defined bone tumor with relevant local aggressiveness
for which in the last 30 years, the surgical resection or
curettage was the only treatment option. No real alterna-
tive existed for locally advanced disease or for difficult
anatomic localizations not susceptible for surgery.
The recent introduction of denosumab has completely
changed the approach and clinical course of the disease.
Denosumab permits with high reliability and low risks
the blockade of local tumor growth and enables less-
invasive surgical procedures [13].
This study focuses on the benefits and risks of com-
bining a surgical treatment of GCTB with neo-adjuvant
or adjuvant denosumab application. It is retrospective
and the patients were not randomized for treatment, so
selecting bias may exist. The indication for denosumab,
thus indirectly the inclusion in the study, was decided by
a multidisciplinary board. As a consequence, only locally
aggressive, extended tumor lesions were enrolled. Our
results are therefore not applicable for latent (grade 1)
or active (grade 2) lesion in GCTB.
We observed in 40 % a surgical downstaging attributable
to the denosumab treatment, decreasing the percentage of
large resections from 64 to 24 %. The percentage of pa-
tients who underwent a less-invasive surgical procedure as
planned at the study entry was the same as previously
reported [14] in a multicenter study.
But also, patients who experienced no surgical downsta-
ging benefit from denosumab treatment as the resection
procedure is facilitated. The decrease of microvascular
density reduces the intraoperative bleeding, and the in-
creased bone density simplifies the intraoperative manipu-
lation and prevents an unintended burst of the tumor.
Interestingly, our local recurrence rate however is
slightly lower compared to other patients treated with
denosumab and surgery (8 vs. 15 %) [14]. We assume
the type of curettage and the use of local intraoperative
adjuvants as the possible reasons. Histologically, the giant
Fig. 2 Resection after denosumab treatment. Radiographic findings of case 17 before (a) and after (b) denosumab treatment. Intraoperative
presentation of the tumor (c) and implantation of an allograft prosthetic composite (d)
Fig. 3 Curettage after denosumab treatment. Intraoperative findings after curettage of the tumor in case nr. 12 (a). Introducing of several probes
inside the cavity, freezing the previous applied thermoconducting and liquid gel to −100 °C, and creating an “ice ball” (b)
Müller et al. World Journal of Surgical Oncology  (2016) 14:281 Page 5 of 7
cells disappeared almost completely, but the stromal cells
persisted, which represent the true neoplastic cells [16].
Although they are fewer and less proliferating, they are
still alive and likely able to reactivate after the end of the
therapy. After the complete simple curettage, a peripheral
rim of new-formed bone is present with multiple lacunae
inside where tumor cells remain (“honey comb”).
In contrary to the soft tumor mass in untreated GCTB,
the denosumab-induced changes necessitate a much more
aggressive curettage technique. We highly suggest the use
of a high-speed burr and local adjuvants to reach the
remaining tumor in the re-ossificated zones. The intraop-
erative use of phenol, peroxide water, or liquid nitrogen is
described to improve local control in curettage procedures
[7, 17–20]. We preferred the application of cryotherapy as
the penetration depth in the surrounding bone is probably
the best [19]. Liquid nitrogen has the same effect as our
performed technique with probes. However, the probes
create a predictable zone of ice around the tip, reducing
the risks and complications for the soft tissue close to
the lesion.
Table 2 Treatment overview
Patient Drug response Surgical downstaging Performed surgery Filling after curettage Local recurrence
1 Yes Yes Curettage + plate fixation Cement (Yes)
2 Yes No Curettage Bone allograft No
3 Yes Yes Curettage + plate fixation Cement No
4 Yes No Curettage Cement No
5 Yes No Curettage + plate fixation Cement No
6 Yes No Soft tissue excision N/A No
7 Yes No Curettage Cement Yes
8 Yes Yes Curettage Cement + bone allograft No
9 Yes No Curettage Bone allograft No
10 No No Resection and APC N/A No
11 Yes Yes Curettage Bone allograft No
12 Yes Yes Curettage + plate fixation Cement No
13 Yes Yes Curettage + plate fixation Cement No
14 Yes Yes Curettage Bone allograft No
15 No No Curettage + screw Cement No
16 Yes No Bone resection N/A No
17 No No Resection and APC N/A No
18 Yes No Bone resection N/A No
19 Yes No Bone resection N/A No
20 Yes Yes Curettage + plate fixation Cement + bone allograft No
21 Yes Yes Curettage Bone allograft No
22 Yes No Curettage + plate fixation Cement No
23 Yes No Curettage Bone allograft No
24 No No Curettage + plate fixation Cement No
25 Yes Yes Curettage Bone allograft No
APC allograft prosthetic composite, N/A not applicable
Fig. 4 Histologic appearance after denosumab treatment. Histologic
appearance of denosumab-treated giant cell tumor of bone. The
residual tumor is composed of bland spindle cells organized in
short fascicles, associated with collagen matrix production. No
osteoclast-like multinucleated giant cells are present
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No new safety risks were observed in this case series
concerning the denosumab treatment, as no adverse effect
occurred. But osteonecrosis of the jaw and hypocalcemia,
although at low rates, are known serious side effects [21].
A total of four patients (16 %) were classified as non-
responder as the tumor was progressive under denosu-
mab treatment. In all these cases, the surgical indication
had not to be changed, and the patients had no negative
consequences. But there is an undeniable risk to trans-
form an acute treatable disease in a chronic disease with
possible worsening of the local situation. Until now, there
are no predisposing or risk factors known for anticipating
a denosumab treatment failure.
Conclusions
Denosumab seems to be an important help to the onco-
logic surgeon by reconstituting a peripheral rim, reducing
intraoperative bleeding, and switching the stage from ag-
gressive to active or latent disease. All these factors lead to
a surgical downstaging facilitating the procedure. But as
tumor cells remain in the new-formed bone, the surgical
technique of curettage has to be changed from gentle to
more aggressive using high-speed burr and local adjuvant.
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